Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $2.2 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 7089.09% year-over-year to $2.2 billion; the TTM figure through Jun 2026 stood at $3.2 billion (up 325.14% YoY), while the FY2025 annual figure was -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities came in at $2.2 billion for Q2 2026 at Core Scientific, up from $971.4 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $2.2 billion in Q2 2026 to a low of -$45.1 million in Q3 2022.
• Average Cash from Financing Activities over 5 years is $233.9 million, with a median of -$2.6 million recorded in 2023.
• Year-over-year, Cash from Financing Activities plunged 148.04% in 2023 and surged 23239.16% in 2026.
• Over 5 years, Cash from Financing Activities stood at $38.1 million in 2022, then sank by 148.04% to -$18.3 million in 2023, then jumped by 3369.23% to $598.2 million in 2024, then slumped by 103.65% to -$21.8 million in 2025, then surged by 10282.38% to $2.2 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $2.2 billion in Q2 2026, $971.4 million in Q1 2026, and -$21.8 million in Q4 2025.